Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations ; volume:13 ; number:1 ; day:4 ; month:1 ; year:2023 ; pages:1-10 ; date:12.2023
Scientific reports ; 13, Heft 1 (4.1.2023), 1-10, 12.2023
- Urheber
-
Imam, Mohamed S.
Batubara, Afnan S.
Gamal, Mohammed
Abdelazim, Ahmed H.
Almrasy, Ahmed A.
Ramzy, Sherif
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-26944-y
- URN
-
urn:nbn:de:101:1-2023031321141516456251
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Imam, Mohamed S.
- Batubara, Afnan S.
- Gamal, Mohammed
- Abdelazim, Ahmed H.
- Almrasy, Ahmed A.
- Ramzy, Sherif
- SpringerLink (Online service)
Ähnliche Objekte (12)
Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms
Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms
Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor